When Israel-based Teva Pharmaceuticals Ltd. announced to investors in July that it would be acquiring Barr Pharmaceuticals, Inc., based in New Jerseythus making what was by far the world’s largest generic drug maker even biggerthe company had a lot to tell its investors. But there was one question the company wasn’t interested in answering.
Teva North America’s president and CEO, William Marth, artfully dodged an analyst’s inquiry about whether the postmerger company would have a greater appetite for “at-risk” product launchesthe controversial and dangerous move that Teva and other generic companies have executed increasingly over the past few years. “We really respect the Barr legal team,” said Marth. (Barr’s management is perhaps best known for breaking the patent on Eli Lilly’s Prozac.) They have a “really, really good legal strategy,” Marth addedand stayed mum on the combined companies’ legal plans.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
